This is a summary of a research study called ARROW, which tested a medicine called pralsetinib in patients with non-small cell lung cancer (NSCLC), thyroid cancer, and other advanced solid tumours caused by a change in a gene called RET. For the purposes of this summary, only patients with NSCLC with a change in RET called fusion (RET fusion+) are highlightedThis Plain Language Summary of Publication article from Future Oncology summarises a study called ARROW. The study tested a medicine called pralsetinib in patients with non-small cell lung cancer (NSCLC), thyroid cancer, and other advanced solid tumours caused by a change in a gene called RET.

Visit the Future Medicine site using the link to read to the full article.

The original article on which this summary is based is called ‘Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial’ and was published in Annals of Oncology.

Visit the Annals of Oncology site using the link to read the article.